Screener
Cytek Biosciences, Inc. CTKB Debt Issuance Proceeds
Debt Issuance Proceeds at other companies
Other financials
Where this comes from
Reported directly by Cytek Biosciences, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromLinesOfCredit.
The source filing: Cytek Biosciences, Inc.’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 5:06 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-053496
| (In thousands) | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Proceeds from Employee Stock Purchase Plan | 851 | 703 |
| Payments for taxes related to net share settlement of equity awards | (423) | (231) |
| Proceeds from issuance of common stock under employee stock plans | 112 | 103 |
| Proceeds from line of credit | 5,109 | 2,075 |
| Payments for repurchase of shares | — | (15,137) |
| Net cash provided by (used in) financing activities | 3,167 | (14,147) |
| Effect of exchange rate changes on cash and cash equivalents | 1,252 | (2,149) |
| Cash and cash equivalents: |
Item 1. Consolidated Financial Statements (Unaudited)
FAQ
- What is Cytek Biosciences, Inc.'s debt issuance proceeds?
- Cytek Biosciences, Inc. (CTKB) reported debt issuance proceeds of $41K in Q2 2026.
- How has Cytek Biosciences, Inc.'s debt issuance proceeds changed year-over-year?
- Cytek Biosciences, Inc.'s debt issuance proceeds decreased by 97.0% year-over-year, from $1.39M to $41K.
- What does debt issuance proceeds mean?
- Cash received from issuing bonds, notes, term loans, and other debt instruments in the capital markets or from bank lending.
Ask your AI about Cytek Biosciences, Inc.'s debt issuance proceeds.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude